Please assess the completion status of the following clinical trial:

Trial Title: Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection as documented by screening plasma HIV-1 RNA \>1000 c/mL~* ART-naïve (short-term antiretroviral use for prevention of mother-to-child transmission will be allowed) or~* ART treatment interrupters on ART \<6 months prior to interruption or virologically suppressed (\<50 copies/mL or LDL) \<6 months prior to interruption~* On rifampicin-based therapy for tuberculosis for \<3 months~* CD4 counts \>100 cells/µL~* Women of child-bearing potential willing to use adequate contraception (defined as either an intrauterine contraceptive device or hormonal contraception as per national guidelines)~Exclusion Criteria:~* Pregnant/breastfeeding~* Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2 (calculated by the Modification of Diet in Renal Disease (MDRD) study)~* Alanine aminotransferase \>3 times upper limit of normal (ULN)~* Allergy or intolerance to one of the drugs in regimen~* Concomitant medication known to significantly reduce or increase dolutegravir exposure (except rifampicin)~* Active psychiatric disease or substance abuse~* On treatment for active AIDS-defining condition other than tuberculosis (participants on maintenance therapy may be enrolled)~* Malignancy~* Any other clinical condition that in the opinion of an investigator puts the patient at increased risk of participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Supplementary dose (Type: ACTIVE_COMPARATOR): Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later.
- Placebo dose (Type: PLACEBO_COMPARATOR): Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with placebo taken 12 hours later.

Based on this trial design, predict the completion outcome and termination type (if applicable).